ATE485836T1 - Mrt-geführte photodynamische therapie gegen krebs - Google Patents
Mrt-geführte photodynamische therapie gegen krebsInfo
- Publication number
- ATE485836T1 ATE485836T1 AT05853048T AT05853048T ATE485836T1 AT E485836 T1 ATE485836 T1 AT E485836T1 AT 05853048 T AT05853048 T AT 05853048T AT 05853048 T AT05853048 T AT 05853048T AT E485836 T1 ATE485836 T1 AT E485836T1
- Authority
- AT
- Austria
- Prior art keywords
- mri
- photodynamic therapy
- cancer
- treatment
- disclosed
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002428 photodynamic therapy Methods 0.000 title abstract 3
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 4
- 239000003504 photosensitizing agent Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000002616 MRI contrast agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000005286 illumination Methods 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Laser Surgery Devices (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63325504P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/044012 WO2006060797A2 (en) | 2004-12-03 | 2005-12-02 | Mri guided photodynamic therapy for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485836T1 true ATE485836T1 (de) | 2010-11-15 |
Family
ID=36565853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05853048T ATE485836T1 (de) | 2004-12-03 | 2005-12-02 | Mrt-geführte photodynamische therapie gegen krebs |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090076571A1 (enExample) |
| EP (1) | EP1830879B1 (enExample) |
| JP (1) | JP2008522666A (enExample) |
| KR (1) | KR20070086803A (enExample) |
| AT (1) | ATE485836T1 (enExample) |
| AU (1) | AU2005311560A1 (enExample) |
| CA (1) | CA2589881A1 (enExample) |
| DE (1) | DE602005024437D1 (enExample) |
| WO (1) | WO2006060797A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206736B1 (en) | 2005-12-05 | 2012-02-08 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
| US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
| JP2010526159A (ja) * | 2007-04-10 | 2010-07-29 | 日東電工株式会社 | 多機能性ポリグルタミン酸塩薬物担体 |
| EP2155253A2 (en) * | 2007-05-09 | 2010-02-24 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| WO2009055542A1 (en) * | 2007-10-26 | 2009-04-30 | University Of Utah Research Foundation | Use of mri contrast agents for evaluating the treatment of tumors |
| US20120184495A1 (en) * | 2009-06-12 | 2012-07-19 | Amrita Vishwa Vidyapeetham University Kerala | Targeted nano-photomedicines for photodynamic therapy of cancer |
| WO2013119957A1 (en) * | 2012-02-10 | 2013-08-15 | Aidan Research And Consulting, Llc | Weight reduction through inactivation of gastric orexigenic mediator producing cells |
| TW201514188A (zh) * | 2013-03-13 | 2015-04-16 | Lantheus Medical Imaging Inc | 製備釓磷維塞三鈉單水合物之方法 |
| CN114870014B (zh) * | 2022-05-18 | 2023-07-07 | 南京邮电大学 | 一种多功能抗肿瘤高分子药物及其制备方法和用途 |
| WO2025160349A1 (en) * | 2024-01-25 | 2025-07-31 | Ovokaitys Todd Frank | Methods and systems for improving photodynamic therapy by increasing depth of penetration without concurrently increasing energy deposition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594136A (en) * | 1989-12-21 | 1997-01-14 | Pharmacyclics, Inc. | Texaphyrin solid supports and devices |
| WO1998026747A2 (en) * | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
| DE19831217A1 (de) * | 1998-07-03 | 2000-01-05 | Schering Ag | Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik |
| US6534040B2 (en) * | 1999-12-23 | 2003-03-18 | Health Research, Inc. | Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
| WO2002087632A1 (en) * | 2001-05-02 | 2002-11-07 | Metaprobe, Inc. | High throughput screening methods using magnetic resonance imaging agents |
-
2005
- 2005-12-02 WO PCT/US2005/044012 patent/WO2006060797A2/en not_active Ceased
- 2005-12-02 DE DE602005024437T patent/DE602005024437D1/de not_active Expired - Lifetime
- 2005-12-02 EP EP05853048A patent/EP1830879B1/en not_active Expired - Lifetime
- 2005-12-02 JP JP2007544609A patent/JP2008522666A/ja not_active Withdrawn
- 2005-12-02 AU AU2005311560A patent/AU2005311560A1/en not_active Abandoned
- 2005-12-02 AT AT05853048T patent/ATE485836T1/de not_active IP Right Cessation
- 2005-12-02 CA CA002589881A patent/CA2589881A1/en not_active Abandoned
- 2005-12-02 US US11/792,206 patent/US20090076571A1/en not_active Abandoned
- 2005-12-02 KR KR1020077014910A patent/KR20070086803A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006060797A3 (en) | 2006-08-24 |
| CA2589881A1 (en) | 2006-06-08 |
| WO2006060797A2 (en) | 2006-06-08 |
| AU2005311560A1 (en) | 2006-06-08 |
| KR20070086803A (ko) | 2007-08-27 |
| JP2008522666A (ja) | 2008-07-03 |
| US20090076571A1 (en) | 2009-03-19 |
| EP1830879A4 (en) | 2008-09-17 |
| DE602005024437D1 (de) | 2010-12-09 |
| EP1830879A2 (en) | 2007-09-12 |
| EP1830879B1 (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | NIR-II light in clinical oncology: opportunities and challenges | |
| Dupont et al. | INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): study protocol for a phase I clinical trial | |
| Beck et al. | Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5‐aminolevulinic acid induced protoporphyrin IX | |
| Bechet et al. | Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies | |
| Detappe et al. | Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy | |
| Meyers et al. | Peptide‐targeted gold nanoparticles for photodynamic therapy of brain cancer | |
| Allison | Photodynamic therapy: oncologic horizons | |
| Rosenthal et al. | The status of contemporary image-guided modalities in oncologic surgery | |
| M. Scherer et al. | New approaches to photodynamic therapy from types I, II and III to type IV using one or more photons | |
| Jin et al. | Nanoparticle‐Enabled Selective Destruction of Prostate Tumor Using MRI‐Guided Focal Photothermal Therapy | |
| Bugaj | Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer-clinician’s insight | |
| Shackley et al. | Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours | |
| Arumainayagam et al. | Photodynamic therapy for focal ablation of the prostate | |
| Chin et al. | Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6–polyvinylpyrrolidone | |
| Liu et al. | RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery | |
| Vaidya et al. | Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment | |
| ATE485836T1 (de) | Mrt-geführte photodynamische therapie gegen krebs | |
| Komolibus et al. | Perspectives on interstitial photodynamic therapy for malignant tumors | |
| Schaffer et al. | Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report | |
| Shliakhtsin et al. | Pharmacokinetics and biodistribution of Photolon®(Fotolon®) in intact and tumor-bearing rats | |
| JP2008522666A5 (enExample) | ||
| CN103330938A (zh) | 肿瘤靶向性光敏剂及其制备方法与应用 | |
| Spangler et al. | Optimization of targeted two-photon PDT triads for the treatment of head and neck cancers | |
| RU2204426C1 (ru) | Способ фотодинамической диагностики и терапии больных первично-множественным раком кожи | |
| Yang et al. | An esterase-activated prodrug against pancreatic cancer by imaging-guided photodynamic immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |